相似文献
1
Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.
J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab166.
2
Inactivated vaccine Covaxin/BBV152: A systematic review.
Front Immunol. 2022 Aug 9;13:863162. doi: 10.3389/fimmu.2022.863162. eCollection 2022.
3
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
EBioMedicine. 2022 Apr;78:103938. doi: 10.1016/j.ebiom.2022.103938. Epub 2022 Mar 16.
4
Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
Int J Infect Dis. 2022 Sep;122:693-702. doi: 10.1016/j.ijid.2022.07.033. Epub 2022 Jul 16.
5
Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
Front Immunol. 2022 Sep 23;13:928501. doi: 10.3389/fimmu.2022.928501. eCollection 2022.
6
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).
Front Immunol. 2022 Dec 8;13:1063679. doi: 10.3389/fimmu.2022.1063679. eCollection 2022.
7
Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study.
Lancet Reg Health Southeast Asia. 2023 Jan 24;12:100141. doi: 10.1016/j.lansea.2023.100141.
8
Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.
J Med Virol. 2022 Apr;94(4):1696-1700. doi: 10.1002/jmv.27461. Epub 2021 Nov 25.
9
Covid-19 Vaccines Available in India.
Comb Chem High Throughput Screen. 2022;25(14):2391-2397. doi: 10.2174/1386207325666220315115953.
10
A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19.
Nat Commun. 2022 Sep 17;13(1):5466. doi: 10.1038/s41467-022-33146-7.
引用本文的文献
1
Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5-included SARS-CoV-2 variants than homologous vaccination of mRNA vaccine.
MedComm (2020). 2023 Mar 10;4(2):e238. doi: 10.1002/mco2.238. eCollection 2023 Apr.
2
Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
PLoS One. 2022 Oct 27;17(10):e0276759. doi: 10.1371/journal.pone.0276759. eCollection 2022.
3
A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects.
Front Immunol. 2022 Sep 13;13:940715. doi: 10.3389/fimmu.2022.940715. eCollection 2022.
4
Inactivated vaccine Covaxin/BBV152: A systematic review.
Front Immunol. 2022 Aug 9;13:863162. doi: 10.3389/fimmu.2022.863162. eCollection 2022.
5
SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India.
JAMA Netw Open. 2022 Jan 4;5(1):e2142210. doi: 10.1001/jamanetworkopen.2021.42210.
6
Heterologous prime-boost strategies for COVID-19 vaccines.
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taab191.
Zotero 插件